Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Psychopharmacology"
DOI: 10.1097/jcp.0000000000001575
Abstract: Abstract Purpose/Background Centanafadine is an inhibitor of norepinephrine, dopamine, and serotonin reuptake transporters under investigation for the treatment of attention-deficit/hyperactivity disorder (ADHD). Methods/Procedures Two phase 3 randomized, double-blind, placebo-controlled, parallel-group studies of 200 mg/d or… read more here.
Keywords: attention deficit; placebo; efficacy; centanafadine ... See more keywords
Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2024.30.6.528
Abstract: BACKGROUND Head-to-head trials comparing centanafadine, an investigational therapy for adults with attention-deficit/hyperactivity disorder (ADHD), with other treatment options are lacking. OBJECTIVE To compare safety and efficacy outcomes of centanafadine sustained-release vs lisdexamfetamine dimesylate (lisdexamfetamine), atomoxetine… read more here.
Keywords: comparison; centanafadine; lisdexamfetamine; atomoxetine ... See more keywords